FDA warned Jordan’s Crossing Herbal Connections that its Germaphobe’s Delight Spray was an unapproved, misbranded drug with COVID-19 claims.
What happened
On July 14, 2021, FDA reviewed the company’s website and a YouTube video and found the Germaphobe’s Delight Spray offered for sale with claims it could mitigate, prevent, treat, diagnose, or cure COVID-19. FDA says the product is therefore an unapproved new drug and a misbranded drug. FDA found this through the website and video review, not an inspection.
What FDA found
FDA says the spray is an unapproved new drug because it is intended to treat or prevent COVID-19 without FDA approval.
Section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)FDA says the product is misbranded—misleadingly labeled—because its website and video claims misrepresent it as safe or effective for COVID-19.
Section 502 of the FD&C Act, 21 U.S.C. § 352FDA says introducing the product into interstate commerce is prohibited.
Sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
What FDA wants
FDA asks the company to take immediate action to stop selling unapproved and unauthorized COVID-19 products. Within 48 hours, the company must email the specific steps it has taken, how it will prevent recurrence, and related documentation to COVID-19-Task-Force-CDER@fda.hhs.gov.
Who should pay attention
- retailers and online marketplaces selling herbal sprays
- companies making COVID-19 prevention or treatment claims
- makers of essential-oil sprays marketed as drugs
This is a summary. Read the original letter on fda.gov.